Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial
Checkpoint inhibitor atezolizumab produces lasting responses in a rare aggressive lymphoma where treatment options are severely limited, potentially extending survival for heavily pretreated patients.
This multicenter phase II trial demonstrates that atezolizumab monotherapy produces durable responses in heavily pretreated extranodal NK/T-cell lymphoma, a rare and aggressive lymphoma with very limited second-line options. PD-L1 structural variations (detected in 36% of patients) and PD-L1 expression may serve as predictive biomarkers that could guide patient selection for checkpoint inhibitor therapy.
What the study was
- Study design
- Single-arm multicenter phase II clinical trial
- Population
- Patients with relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL)
- Sample size
- 14
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood Advances
Why it surfaced
Phase II trial in R/R ENKTL, a rare lymphoma with extremely limited effective options; 54% ORR with durable CRs is clinically meaningful; PD-L1 biomarker data adds precision oncology value; registered trial (jRCT2031190177).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.